NSC61610 is a LANCL2 ligand. NSC61610 showed anti-inflammatory activity and potential useful for inflammatory bowel disease and influenza-driven inflammation . LANCL2 is a novel therapeutic target for the discovery and development of new classes of orally bioavailable drugs against chronic metabolic, immune-mediated and infectious diseases. References: Zhang Q, He Q, Xue F, Ma J. Inhibitor screening of lactate dehydrogenase C4 from black-lipped pika in the Western Sichuan Plateau. Biosci Biotechnol Biochem. 2014;78(4):651-4. doi: 10.1080/09168451.2014.890038. PubMed PMID: 25036963.

纯度：≥98%

CAS：500538-94-3